良、恶性肝病、卵巢疾病和胰腺疾病患者血清AFP、CEA、CA125和CA199水平的相关研究

目的:血清中AFP、CEA、CA125和CA199的测定研究良、恶性肝病、卵巢疾病和胰腺疾病诊断的临床意义.方法:发光免疫分析测定了52例正常对照组,68例良性肝病,65例肝癌,56例卵巢疾病和51例胰腺疾病的血清中AFP、CEA、CA125和CA199水平,批内CV＜5%,批间CV＜10%.结果:良性疾病患者的血清四项肿瘤标记物水平大致与对照组的相似(p＞0.05).原发性和继发性肝癌患者的血清CA125和CA199水平较对照组显著升高(p＜0.001).卵巢癌与胰腺癌患者也同样如此(0.001＜p＜0.05).结论:血清AFP、CEA、CA125和 CA199的联合测定是诊断和鉴别肝癌、卵巢癌和胰腺癌的最好方法.

Study on the Serum Levels of AFP, CEA, CA125 and CA199 in Patients with Benign and Malignant Hepatic, Ovarian and Pancreatic Diseases

Objective To study the clinical significance of determining serum AFP, CEA, CA 125 and CA 199 levels in patients with benign and malignant hepatic, ovarian and pancreatic diseases. Methods Serum AFP, CEA, CA 125 and CA 199 levels were determined with luminescent immunoassay in 52 controls, 68 patients with benign liver diseases, 65 patients with liver cancer, 56 patients with ovarian diseases (benign 18, malignant 36) and 51 patients with pancreatic diseases (benign 80, malignant 21). The mean coefficient of variation for intra-and inter-batch assay were less than 5% and 10% respectively. Results The serum levels of AFP, CEA, CA 125 and CA 199 were about the same in patients with benign diseases and normal controls ( p >0 05). The levels of CA 125 and CA 199 in patients with primary and secondary liver cancer were significantly higher than those in normal controls ( p <0 001). The same was true for patients with ovarian and pancreatic cancer (0 001< p <0 05). Conclusion Combined determination of serum levels of AFP, CEA, CA 125 and CA 199 was the best means for the clinical and differential diagnosis of liver, ovary and pancreatic cancers.